Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - Eli Lilly
Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial CNBC Lilly’s Retatrutide Shows Significant Improvement In Weight Loss and Blood Sugar WSJ Lilly’s Experimental Diabetes Shot Yields Record Weight Loss in Study Bloomberg.com Eli Lilly’s ‘triple-G’ drug leads to significant blood sugar, weight reductions in diabetes trial statnews.com